OTCMKTS:CVSI

CV Sciences Stock Forecast, Price & News

$0.43

-0.03 (-6.52 %)

(As of 11/25/2020 12:00 AM ET)

Add

Compare

Today's Range

$0.40

Now: $0.43▼

$0.46

50-Day Range

$0.45

MA: $0.48▼

$0.54

52-Week Range

$0.25

Now: $0.43▼

$1.34

Volume1.03 million shs

Average Volume527,729 shs

Market Capitalization$43.24 million

P/E RatioN/A

Dividend YieldN/A

Beta0.3

CV Sciences, Inc. operates as a life science company. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets hemp-based cannabidiol (CBD) products under the name of PlusCBD in a range of market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. Its products product candidates are based on proprietary formulations, processes, and technology. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
CV Sciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.13, CV Sciences has a forecasted upside of 163.6% from its current price of $0.43.
Amount of Analyst Coverage
CV Sciences has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
CV Sciences has received 213 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
CV Sciences has received 192 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
CV Sciences has received 52.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about CV Sciences and other stocks. Vote “Outperform” if you believe CVSI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVSI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
CV Sciences does not currently pay a dividend.
Dividend Growth
CV Sciences does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CV Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 14.60% of the stock of CV Sciences is held by insiders.
Percentage Held by Institutions
Only 0.01% of the stock of CV Sciences is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for CV Sciences are expected to grow in the coming year, from ($0.13) to ($0.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CV Sciences is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CV Sciences is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CV Sciences has a P/B Ratio of 2.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.30 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolOTCMKTS:CVSI

Previous SymbolNASDAQ:CVSI

CUSIPN/A

CIK1510964

Webwww.cvsciences.com

Phone866-290-2157

Employees118

Debt

Debt-to-Equity Ratio0.13

Current Ratio1.93

Quick Ratio1.24

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$53.70 million

Price / Sales0.81

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.19 per share

Price / Book2.26

Profitability

EPS (Most Recent Fiscal Year)($0.17)

Net Income$-16,610,000.00

Net Margins-68.90%

Return on Equity-81.99%

Return on Assets-42.70%

Miscellaneous

Outstanding Shares100,550,000

Market Cap$43.24 million

Next Earnings Date3/15/2021 (Estimated)

OptionableNot Optionable

$0.43

-0.03 (-6.52 %)

(As of 11/25/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CVSI News and Ratings via Email

Sign-up to receive the latest news and ratings for CVSI and its competitors with MarketBeat's FREE daily newsletter.

CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions

How has CV Sciences' stock price been impacted by Coronavirus (COVID-19)?

CV Sciences' stock was trading at $0.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CVSI stock has decreased by 28.3% and is now trading at $0.43.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of CV Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CV Sciences.

What stocks does MarketBeat like better than CV Sciences?

Wall Street analysts have given CV Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CV Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CV Sciences' next earnings date?

CV Sciences is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for CV Sciences.

How were CV Sciences' earnings last quarter?

CV Sciences, Inc. (OTCMKTS:CVSI) announced its quarterly earnings results on Thursday, November, 5th. The company reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The business had revenue of $5.56 million for the quarter, compared to analysts' expectations of $6.32 million. CV Sciences had a negative return on equity of 81.99% and a negative net margin of 68.90%.
View CV Sciences' earnings history.

What price target have analysts set for CVSI?

4 analysts have issued 12-month price objectives for CV Sciences' stock. Their forecasts range from $0.75 to $1.70. On average, they expect CV Sciences' stock price to reach $1.13 in the next twelve months. This suggests a possible upside of 163.6% from the stock's current price.
View analysts' price targets for CV Sciences.

Who are some of CV Sciences' key competitors?

Some companies that are related to CV Sciences include GlycoMimetics (GLYC), Sol-Gel Technologies (SLGL), Rezolute (RZLTD), Minerva Neurosciences (NERV), Checkpoint Therapeutics (CKPT), 9 Meters Biopharma (NMTR), Biofrontera (BFRA), Sierra Oncology (SRRA), Taiwan Liposome (TLC), Tiziana Life Sciences (TLSA), Matinas BioPharma (MTNB), ContraFect (CFRX), Ritter Pharmaceuticals (RTTR), Ampio Pharmaceuticals (AMPE) and LifeVantage (LFVN).
View all competitors.

What other stocks do shareholders of CV Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Charlotte's Web (CWBHF), KushCo (KSHB), Aphria (APHA), OrganiGram (OGI), GW Pharmaceuticals (GWPH), Tilray (TLRY) and Medical Marijuana (MJNA).

Who are CV Sciences' key executives?

CV Sciences' management team includes the following people:

Mr. Joseph D. Dowling, CEO, Sec. & Director (Age 63, Pay $708.77k)
Mr. Joerg Grasser, Chief Financial Officer (Age 45, Pay $389.23k)
Dr. Douglas Jesse MacKay ND, Sr. VP of Scientific & Regulatory Affairs (Age 47)

What is CV Sciences' stock symbol?

CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."

How do I buy shares of CV Sciences?

Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CV Sciences' stock price today?

One share of CVSI stock can currently be purchased for approximately $0.43.

How big of a company is CV Sciences?

CV Sciences has a market capitalization of $43.24 million and generates $53.70 million in revenue each year. The company earns $-16,610,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. CV Sciences employs 118 workers across the globe.

What is CV Sciences' official website?

The official website for CV Sciences is www.cvsciences.com.

How can I contact CV Sciences?

CV Sciences' mailing address is 10070 BARNES CANYON ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at 866-290-2157 or via email at [email protected]

This page was last updated on 11/27/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings